AnaptysBio, Inc. (ANAB)
NASDAQ · Manufacturing · Pharmaceutical preparations
ANAB price, last 12 months
Key stats
- Previous close
- $47.06
- Open
- $48.41
- Day range
- $46.86 – $49.71
- 52-week range
- $33.10 – $73.30
- Volume
- 507K
- Avg volume (20 days)
- 387.7K
- Market cap
- $1.4B
Performance
Technicals and fundamentals
About AnaptysBio, Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.4B